Wnt5a inhibits the CpG oligodeoxynucleotide-triggered activation of human plasmacytoid dendritic cells

Clinical and Experimental Dermatology

Volumn 37, Issue 5, 2012, Pages 557-561

  Hack, K ^a,b   Reilly, L ^a,b   Proby, C ^a,b,c   Fleming, C ^c   Leigh, I ^a,b,c   Foerster, John ^b,c,d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9; WNT5A PROTEIN;

ARTICLE; CELL ACTIVATION; CELL SIZE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSKELETON; HUMAN; HUMAN CELL; IMMUNOREGULATION; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; UPREGULATION;

ANTIGENS, CD80; ANTIGENS, CD86; DENDRITIC CELLS; HUMANS; INTERFERON-ALPHA; MELANOMA; OLIGODEOXYRIBONUCLEOTIDES; PROTO-ONCOGENE PROTEINS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION; WNT PROTEINS;

EID: 84862888212     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2012.04362.x     Document Type: Article

References (13)

1. Dillman RO, Selvan SR, Schiltz PM et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biotherapy Radiopharm 2009; 24: 311-19.
2. Charles J, Di Domizio J, Salameire D et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol 2010; 1646: 130-56.
3. Gerlini G, Di Gennaro P, Mariotti G et al. Indoleamine 2,3- dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes. J Invest Dermatol 2010; 130: 898-901.
4. Gerlini G, Urso C, Mariotti G et al. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol 2007; 125: 184-93. (Pubitemid 47562900)
5. Matsumoto S, Fumoto K, Okamoto T et al. Binding of APC and dishevelled mediates Wnt5a-regulated focal adhesion dynamics in migrating cells. EMBO J 2010; 29: 1192-204.
6. Dissanayake SK, Wade M, Johnson CE et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007; 282: 17259-71. (Pubitemid 47093253)
7. Krug A, Towarowski A, Britsch S et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31: 3026-37. (Pubitemid 32994554)
8. Kerkmann M, Rothenfusser S, Hornung V et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003; 170: 4465-74. (Pubitemid 36519951)
9. Sanjuan MA, Rao N, Lai KT et al. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol 2006; 172: 1057-68.
10. Weeraratna AT, Jiang Y, Hostetter G et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1: 279-88. (Pubitemid 41039152)
11. Rajagopal D, Paturel C, Morel Y et al. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2011; 115: 1949-57.
12. Shinohara ML, Lu L, Bu J et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nature Immunol 2006; 7: 498-506.
13. Valencia J, Hernandez-Lopez C, Martinez VG et al. Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. J Immunol 2011; 187: 4129-39.